AstraZeneca plc (LON:AZN) had its target price increased by equities researchers at Jefferies Group from GBX 5,800 ($71.78) to GBX 6,000 ($74.26) in a research report issued to clients and investors on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s target price suggests a potential upside of 21.00% from the company’s current price.

Several other analysts have also recently issued reports on AZN. BNP Paribas reaffirmed an “outperform” rating and set a GBX 5,000 ($61.88) price objective on shares of AstraZeneca plc in a research note on Wednesday, June 15th. HSBC reaffirmed a “hold” rating and set a GBX 4,240 ($52.48) price objective on shares of AstraZeneca plc in a research note on Friday, June 17th. Citigroup Inc. reaffirmed a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a GBX 5,600 ($69.31) price objective on shares of AstraZeneca plc in a research note on Friday, June 24th. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of GBX 4,960.13 ($61.39).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 4958.50 on Thursday. The company’s 50-day moving average is GBX 5,002.62 and its 200 day moving average is GBX 4,463.11. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock’s market capitalization is GBX 62.73 billion.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.